Hepatocellular carcinoma - Pathological complete response to oral capecitabine, megestrol and thalidomide [3]

Acta Oncologica

Volumn 45, Issue 1, 2006, Pages 95-97

  Quek, Richard ^a   Soon, Thye Lim ^a   Ong, Simon ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; MEGESTROL; THALIDOMIDE;

ABDOMINAL ANGIOGRAPHY; AGED; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; HISTOLOGY; HUMAN; LETTER; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TOXICITY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; DISEASE PROGRESSION; HUMANS; MALE; MEGESTROL; THALIDOMIDE; TREATMENT OUTCOME;

EID: 32244439253     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500341140     Document Type: Letter

References (5)

1. Seow A, Koh WP, Chia KS, Shi LM, Lee HP, Shanmugaratnam K. Trends in cancer incidence in Singapore 1968-2002. Singapore Cancer Registry Report No.6.
2. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallblader carcinoma. Cancer 2004;101:578-86.
3. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65:242-9.
4. Villa E, Ferretti I, Grottola A, Buttafoco P, Buono MG, Giannini F, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001;84:881-5.
5. Engstrom PF, Levin B, Moertel CG, Schutt A. A phase II trial of tamoxifen in hepatocellular carcinoma. Cancer 1990;65:2641-3.